Background: Myelofibrosis is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis and extramedullary hematopoiesis leading to splenomegaly. Progressive splenomegaly is common in advanced myelofibrosis, and spleen volume is a predictor of survival. The oral selective small-molecule JAK 1/2 inhibitor ruxolitinib is used for symptomatic management of intermediate-2 and high-risk myelofibrosis, and leads to [...]

Case Presentation: A 25-year-old woman with autism, developmental delay, and seizure disorder presented with weakness, joint pain, and lethargy. Initial findings included pancytopenia, elevated inflammatory markers, and hyperferritinemia. She was diagnosed with hemophagocytic lymphohistiocytosis (HLH) secondary to adult-onset Still’s disease. Despite treatment with corticosteroids, anakinra, and tocilizumab, her condition worsened, necessitating ICU admission. Discussion: HLH [...]